ROCHESTER, Minn. — A new Mayo Clinic study (http://newsblog.mayoclinic.org/2008/12/03/brain-tumors-best-treatments-for-long-term-survival/) found that children with low-grade brain tumors (gliomas) (http://www.mayoclinic.org/brain-tumors/) who under…
ROCHESTER, Minn. — Researchers at Mayo Clinic (http://www.mayoclinic.org/) have found a significant difference in cancer progression and death in chronic lymphocytic leukemia (CLL) patients who had sufficient vitamin D (http://www.mayoclinic.com/he…
A Mayo Clinic study is the first to show that for some patients with early stage multiple myeloma, the drug thalidomide may effectively delay the need for chemotherapy or more aggressive treatment for as much as two years. Multiple myeloma is an incurable cancer of the bone marrow. The final results of the nonrandomized phase II clinical trial were published today in the April issue of the journal Leukemia. Because of the promising indications, preliminary findings were released about a year ago.
A long-term study of patients in Rochester, Minn., with the eating disorder anorexia nervosa found that their survival rates did not differ from the expected survival rates of others of the same age and sex. The results, published in the March issue of Mayo Clinic Proceedings, add to the knowledge of anorexia nervosa and point to other areas that need greater study from researchers. “Although our data suggest that overall mortality is not increased among community patients with anorexia nervosa in general, these findings should not lead to complacency in clinical practice because deaths do occur,” says L. Joseph Melton, III, M.D., Mayo Clinic epidemiologist and an author of the report.
Over one-half of golfers affected by the “yips” report symptoms that strongly suggest a physical rather than psychological origin of the problem, according to findings of a Mayo Clinic study published in the most recent issue of Sports Medicine. The ‘yips’ is a condition that involves a tremor, freezing or involuntary jerking of the hands when attempting golf shots, particularly short putts. Previous research has indicated it adds nearly five strokes to an affected golfer’s 18-hole score.
A new Mayo Clinic study shows that the fears of many related to living into one’s 90s and beyond — getting lost in your own neighborhood; losing the ability to take care of financial affairs; having a driver’s license revoked; ending up in a nursing home — are in many cases unfounded. This research, to be published in the Feb. 11 issue of Neurology, demonstrates that for many age 90 and above, memory can be strikingly sharp even up to one century of age.
An interruption in normal breathing patterns during sleep which is often seen in heart failure patients may contribute to heart failure rather than just being a result, according to findings of a Mayo Clinic study.
“We are now finding that central sleep apnea, which has been previously understood as a symptom of heart failure, may contribute to the development of heart failure in people at risk,” said the study’s lead researcher.
Researchers have produced the first laboratory evidence to show that a cell’s possession of an abnormal numbers of chromosomes contributes to the development of cancers. Their report on the role of this chromosomal instability, known as aneuploidy, appears in today’s online edition of the Feb. 3 Journal of Cell Biology. Because 85 percent of human cancer cells possess an abnormal number of chromosomes, researchers have long been curious about the role of aneuploidy in the multistep cancer process.
Nearly one-third of patients with advanced multiple myeloma who had failed current standard therapy of chemotherapy or stem cell transplantation responded to thalidomide for a median duration of nearly one year in a Mayo Clinic study of the effects of thalidomide on myeloma. The findings are reported in the January issue of Mayo Clinic Proceedings.
Many studies in the last three years have determined that thalidomide is effective in the treatment of multiple myeloma, following the initial report by researchers at the University of Arkansas. However, information is limited on how long thalidomide therapy works and on survival rates with such therapy.
A Mayo Clinic investigation of Interleukin-6, a hormone inside cells often considered a “bad actor” of the immune system because of its association with inflammation injuries and malignant diseases, shows that it also plays a therapeutic role in mice: it protects brain cells. Interleukin-6 — called IL-6 for short by researchers — may, in fact, be a “white knight” for mouse brain cells, or neurons, as brain cells also are called. These results, while early, may be promising for humans as well. The Mayo Clinic investigation is described in the Jan. 15 Journal of Neuroscience.